RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MESSINA M
Collezione AO Cuneo

Items : 2

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino

Fazi P; Vignetti M; Guarini A; Cuneo A; Piciocchi A; De Propris MS; Nanni M; Del Giudice I; Neri A; De Novi LA; Albano F; Vitale C; Visentin A; Pietrasanta D; Mattiello V; Molinari MC; Liberati AM; Giordano A; Patrizi VB; Gottardi D; Galieni P; Deodato M; Arcari A; Musuraca G; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. in Haematologica / Haematologica. 2021 Jun 1;106(6):1559-1568. doi: 10.3324/haematol.2020.247973.

2021
AO Cuneo

Vitale A; Cattaneo C; Mattei D; Fracchiolla N; Cerrano M; Cairoli R; Candoni A; Papayannidis C; De Fabritiis P; Di Raimondo F; Capria S; Apicella V; Spinelli O; Santoro A; Pierini V; Puzzolo MC; Lauretti A; Canichella M; La Starza R; Albertini Petroni G; Elia L; Ansuinelli M; Taherinasab A; Cavalli M; Cafforio L; Piciocchi A; Della Starza I; Messina M; Chiaretti S; et alii...